Patients’ demographic and disease characteristics at study baseline
| Characteristic . | Number of patients (N = 82) . | n (%) . |
|---|---|---|
| Age (y) | ||
| Median | 60 | |
| Range | 25-85 | |
| ≤70 y | 70 | 85 |
| Sex | ||
| Male | 50 | 61 |
| Female | 32 | 39 |
| Ratio | 1:6 | |
| Lymphoma histology | ||
| TFH | 42 | 51 |
| AITL | 40 | 49 |
| Other TFH | 2 | 2 |
| PTCL NOS | 13 | 16 |
| ALCL | 22 | 27 |
| Alk− | 17 | 21 |
| Alk+ | 5 | 6 |
| EATL | 3 | 4 |
| T/NK extranodal | 1 | 1 |
| Subcutaneous panniculitis | 1 | 1 |
| CD30 status∗ | ||
| Positive | 52 | 63 |
| Negative | 21 | 26 |
| Missing | 9 | 11 |
| Stage | ||
| 1-2 | 10 | 12 |
| 3-4 | 71 | 87 |
| Missing | 1 | 1 |
| IPI | ||
| 0-2 | 40 | 49 |
| 3-5 | 30 | 37 |
| Missing | 12 | 14 |
| Number of previous regimen | ||
| Median | 1 | |
| Range | 1-6 | |
| Status at last regimen | ||
| Refractory | 41 | 50 |
| Early relapse (<1 y) | 29 | 35 |
| Late relapse (≥1 y) | 12 | 15 |
| Previous therapy | ||
| CHOP-like regimen | 79 | 96 |
| Cytarabine- and/or platine-based regimen | 29 | 35 |
| Other polychimiotherapy | 13 | 16 |
| New treatments | ||
| HDACi | 4 | 5 |
| BV | 9 | 11 |
| Lenalidomide | 2 | 2 |
| SC transplantation | 25 | 30 |
| Autologous | 21 | 84 |
| Allogeneic | 2 | 8 |
| Autologous + allogeneic | 2 | 8 |
| Characteristic . | Number of patients (N = 82) . | n (%) . |
|---|---|---|
| Age (y) | ||
| Median | 60 | |
| Range | 25-85 | |
| ≤70 y | 70 | 85 |
| Sex | ||
| Male | 50 | 61 |
| Female | 32 | 39 |
| Ratio | 1:6 | |
| Lymphoma histology | ||
| TFH | 42 | 51 |
| AITL | 40 | 49 |
| Other TFH | 2 | 2 |
| PTCL NOS | 13 | 16 |
| ALCL | 22 | 27 |
| Alk− | 17 | 21 |
| Alk+ | 5 | 6 |
| EATL | 3 | 4 |
| T/NK extranodal | 1 | 1 |
| Subcutaneous panniculitis | 1 | 1 |
| CD30 status∗ | ||
| Positive | 52 | 63 |
| Negative | 21 | 26 |
| Missing | 9 | 11 |
| Stage | ||
| 1-2 | 10 | 12 |
| 3-4 | 71 | 87 |
| Missing | 1 | 1 |
| IPI | ||
| 0-2 | 40 | 49 |
| 3-5 | 30 | 37 |
| Missing | 12 | 14 |
| Number of previous regimen | ||
| Median | 1 | |
| Range | 1-6 | |
| Status at last regimen | ||
| Refractory | 41 | 50 |
| Early relapse (<1 y) | 29 | 35 |
| Late relapse (≥1 y) | 12 | 15 |
| Previous therapy | ||
| CHOP-like regimen | 79 | 96 |
| Cytarabine- and/or platine-based regimen | 29 | 35 |
| Other polychimiotherapy | 13 | 16 |
| New treatments | ||
| HDACi | 4 | 5 |
| BV | 9 | 11 |
| Lenalidomide | 2 | 2 |
| SC transplantation | 25 | 30 |
| Autologous | 21 | 84 |
| Allogeneic | 2 | 8 |
| Autologous + allogeneic | 2 | 8 |
Alk; EATL, enteropathy associated T-cell lymphoma; HDACi, histone deacetylase inhibitor; SC, stem cell.
CD30 status determined by immunochemistry, considering only tumor cells with a threshold of 5%.